Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.
The Da Vinci SP made its way to the operating room for doctors at Trident Medical Center. The robot that uses a single port, ...
University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood – ...
University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...
GlobalData on MSN2d
Purple Biotech advances NT219 into Phase II recurrent/metastatic SCCHN studyPurple Biotech has entered a Phase II trial with its small molecule drug, NT219, focusing on patients with ...
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...
EVANSTON, Ill. — Aaron Baltaytis, a Northwestern University varsity swimmer, knows about diving into the deep end. He spends almost every morning in the Norris Aquatics Center pool testing his ...
Purple Biotech (PPBT) is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head ...
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and ...
Aaron Baltaytis, a Northwestern University varsity swimmer, recently received a devastating diagnosis of testicular cancer but was motivated by his team and coaches to continue his rehabilitation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback